Effects of oligos on the growth of human lung cancer A549 xenografts in
C.B-17-scid/scid mice. Each point represents the
mean ± SE of tumor mass from six mice. Oligo AS, administered
orally at 0.5, 5, and 10 mg/kg per day at five doses per week,
demonstrated dose-dependent antitumor activity. Oligo ASM has no
effect, confirming the specificity of Oligo AS.